Trump Forms Partnership with AstraZeneca to Reduce Drug Costs in U.S., Reports MSNBC

According to MSNBC, the U.S. administration under Trump and AstraZeneca, a major pharmaceutical enterprise based in the United Kingdom, have reached a consensus to reduce medication prices in America.

This forthcoming pact with AstraZeneca aligns with a previous arrangement secured with the American drug manufacturer Pfizer, which was publicized at the end of the prior month.

Sources reveal that this agreement is anticipated to be unveiled on Friday during a gathering at the White House with President Trump and Pascal Soriot, the Chief Executive Officer of AstraZeneca, making the announcements. As part of the deal, AstraZeneca is expected to provide medicines to Medicaid beneficiaries at the lowest rates available in other advanced economies, highlighted as "most-favored nation" pricing, on the upcoming government platform named TrumpRx.gov.

Similar terms were reached with Pfizer, including a waiver from tariffs on pharmaceuticals lasting three years, conditional upon Pfizer's commitment to continue investing within the U.S. manufacturing sector.

Currently, it remains uncertain if AstraZeneca's agreement will incorporate such exemptions.

In a statement from July, AstraZeneca expressed intentions to boost the American manufacturing landscape by the end of the decade. Ahead of Friday's announcement, AstraZeneca reaffirmed its commitment to the pricing deal.

As costs for medications rise dramatically compared to other developed nations, there is widespread voter discontent, prompting Trump's administration to push drug manufacturers to bolster production within the U.S. As part of these efforts, potential tariffs reaching 250% have been threatened, compelling several companies to pledge significant investments locally.

Looking forward, Trump expressed ambitions to negotiate similar pricing agreements with additional key pharmaceutical companies in the near future.

In his announcement of the Pfizer deal, Trump declared, "If we don't formalize an agreement, tariffs will be applied," emphasizing a hardline stance on compliance.